Systematic review with meta-analysis of active herpesvirus infections in patients with COVID-19: Old players on the new field.
Int J Infect Dis
; 130: 108-125, 2023 May.
Article
em En
| MEDLINE
| ID: mdl-36736577
ABSTRACT
OBJECTIVES:
Herpesviruses are ubiquitous and after primary infection they establish lifelong latency. The impairment of maintaining latency with short-term or long-term consequences could be triggered by other infection. Therefore, reactivation of herpesviruses in COVID-19 patients represents an emerging issue. DESIGN ANDMETHODS:
This study provided the first systematic review with meta-analysis of studies that evaluated active human herpesvirus (HHV) infection (defined as the presence of IgM antibodies or HHV-DNA) in COVID-19 patients and included 36 publications collected by searching through PubMed, SCOPUS, and Web of science until November 2022.RESULTS:
The prevalence of active EBV, HHV6, HSV, CMV, HSV1, and VZV infection in COVID-19 population was 41% (95% CI =27%-57%), 3% (95% CI=17%-54%), 28% (95% CI=1%-85%), 25% (95% CI=1%-63%), 22% (95% CI=10%-35%), and 18% (95% CI=4%-34%), respectively. There was a 6 times higher chance for active EBV infection in patients with severe COVID-19 than in non-COVID-19 controls (OR=6.45, 95% CI=1.09-38.13, p=0.040), although there was no difference in the prevalence of all evaluated active herpesvirus infections between COVID-19 patients and non-COVID-19 controls.CONCLUSIONS:
Future research of herpesvirus and SARS-CoV-2 coinfections must be prioritized to define who, when and how to be tested, as well as how to effectively treat HHVs reactivations in acute and long COVID-19 patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Herpesvirus Humano 6
/
Infecções por Herpesviridae
/
COVID-19
/
Herpesviridae
Tipo de estudo:
Risk_factors_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article